Mendes M C, Ferriani R A, Sala M M, Moura M D, de Sá M F
Department of Gynecology and Obstetrics, University of São Paulo, Brazil.
Gynecol Endocrinol. 1999 Jun;13(3):149-54. doi: 10.3109/09513599909167548.
Literature data have demonstrated that the chronic use of metoclopramide (MCP), a dopamine antagonist, causes increased gonadotropin secretion in patients with hypothalamic amenorrhea but without triggering ovulation. It has also been observed that women with hypothalamic amenorrhea respond poorly to ovulation induction with clomiphene citrate (CC). On this basis, the objective of the present study was to determine the effect of MCP on the response to CC in patients with hypothalamic amenorrhea in order to evaluate the validity of the simultaneous use of these drugs as ovulation inducers in this type of chronic anovulation. Twenty-two patients with amenorrhea of hypothalamic origin were submitted to a randomized double blind study in which one tablet of 5 mg MCP or placebo was administered every 8 hours for 2 months. After the 30th day of medication (MCP or placebo), CC, 100 mg orally, was additionally administered to both groups for 5 days. Blood samples were collected on days 1, 15 and 30 during the first month of the study and on days 7, 14 and 21 after the last CC tablet during the second month, for later measurement of follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin, estradiol and progesterone by radioimmunoassay. The group that received MCP showed a significant increase in LH and FSH during the first month of the study, as well as a slighter increase in estradiol. Prolactin increased only during the second stage of treatment. No significant increases in gonadotropins, prolactin or estradiol occurred in the placebo group. In the group treated with MCP, 40% of the patients ovulated after CC, with menstruation occurring in 60% of them. In the placebo group, 33.3% of the women ovulated after CC and 44.4% menstruated at the end of the study. We conclude that MCP increases the circulating levels of LH, FSH, estradiol and prolactin in patients with hypothalamic amenorrhea and low estrogen levels, supporting the hypothesis that an increase in hypothalamic dopaminergic tonus occurs in these patients. On the other hand, the combination of MCP and CC does not improve the rate of ovulation compared to placebo.
文献数据表明,长期使用多巴胺拮抗剂甲氧氯普胺(MCP)会导致下丘脑性闭经患者的促性腺激素分泌增加,但不会引发排卵。还观察到,下丘脑性闭经的女性对枸橼酸氯米芬(CC)促排卵治疗反应不佳。在此基础上,本研究的目的是确定MCP对下丘脑性闭经患者对CC反应的影响,以评估这两种药物同时用作此类慢性无排卵促排卵药物的有效性。22例下丘脑性闭经患者接受了一项随机双盲研究,其中每8小时服用1片5 mg的MCP或安慰剂,持续2个月。在用药(MCP或安慰剂)第30天后,两组均额外口服100 mg CC,持续5天。在研究的第一个月的第1、15和30天以及第二个月最后一片CC片剂后的第7、14和21天采集血样,随后通过放射免疫分析法测定促卵泡激素(FSH)、促黄体生成素(LH)、催乳素、雌二醇和孕酮。接受MCP治疗的组在研究的第一个月LH和FSH显著增加,雌二醇也有轻微增加。催乳素仅在治疗的第二阶段增加。安慰剂组的促性腺激素、催乳素或雌二醇无显著增加。在接受MCP治疗的组中,40%的患者在服用CC后排卵,其中60%出现月经。在安慰剂组中,33.3%的女性在服用CC后排卵,44.4%在研究结束时出现月经。我们得出结论,MCP可增加下丘脑性闭经且雌激素水平低的患者的LH、FSH、雌二醇和催乳素的循环水平,支持这些患者下丘脑多巴胺能张力增加的假说。另一方面,与安慰剂相比,MCP和CC联合使用并不能提高排卵率。